However, more recent studies have highlighted novel candidates such as urinary immune complexes, vascular cell adhesion molecule-1 (VCAM-1), and angiostatin, which show promise in improving the diagnosis and management of LN [9]. This evidence concerns the gene VCAM1 and lobular neoplasia.